As of April 28, 2026, Cogent Biosciences's top three insider holders are Andrew R Robbins (President And Ceo, 657.50K shares), Cole Pinnow (Chief Commercial Officer, 216.65K shares), John Edward Robinson (Chief Scientific Officer, 140.00K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Andrew R Robbins | President And Ceo | 657,503 | 0 | 19 Dec, 2025 |
| Cole Pinnow | Chief Commercial Officer | 216,650 | 0 | 19 Dec, 2025 |
| John Edward Robinson | Chief Scientific Officer | 140,002 | 0 | 30 Dec, 2025 |
| Evan Kearns | Chief Legal Officer | 109,398 | 0 | 30 Dec, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 01 Apr, 2026 | Karen Jean Ferrante | Stock Option (Right to Buy) | A | 686 | $0.00 | 686 | D | A |
| 01 Jan, 2026 | Karen Jean Ferrante | Stock Option (Right to Buy) | A | 643 | $0.00 | 643 | D | A |
| 26 Dec, 2025 | Evan Kearns | Common Stock | D | 65,000 | $38.70 | 109,398 | D | S |
| 26 Dec, 2025 | John Edward Robinson | Common Stock | D | 90,000 | $38.74 | 140,002 | D | S |
| 17 Dec, 2025 | John Edward Robinson | Common Stock | A | 50,000 | $0.00 | 50,000 | D | A |
| 17 Dec, 2025 | Cole Pinnow | Common Stock | A | 50,000 | $0.00 | 97,450 | D | A |
| 17 Dec, 2025 | Evan Kearns | Common Stock | A | 40,000 | $0.00 | 40,000 | D | A |
| 17 Dec, 2025 | Andrew R Robbins | Common Stock | A | 185,000 | $0.00 | 185,000 | D | A |
| 17 Dec, 2025 | Evan Kearns | Common Stock | A | 260,000 | $0.00 | 300,000 | D | A |
| 17 Dec, 2025 | Cole Pinnow | Common Stock | A | 214,000 | $0.00 | 311,450 | D | A |
| 17 Dec, 2025 | John Edward Robinson | Common Stock | A | 320,000 | $0.00 | 370,000 | D | A |
| 17 Dec, 2025 | Andrew R Robbins | Common Stock | A | 840,000 | $0.00 | 1,025,000 | D | A |
| 17 Dec, 2025 | Evan Kearns | Common Stock | D | 125,602 | $39.45 | 174,398 | D | F |
| 17 Dec, 2025 | John Edward Robinson | Common Stock | D | 139,998 | $39.45 | 230,002 | D | F |
| 17 Dec, 2025 | Andrew R Robbins | Common Stock | D | 367,497 | $39.45 | 657,503 | D | F |
| 17 Dec, 2025 | Cole Pinnow | Common Stock | D | 94,800 | $39.45 | 216,650 | D | F |
| 17 Dec, 2025 | Evan Kearns | Stock Option (Right to Buy) | A | 55,000 | $0.00 | 55,000 | D | A |
| 17 Dec, 2025 | John Edward Robinson | Stock Option (Right to Buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 17 Dec, 2025 | Cole Pinnow | Stock Option (Right to Buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 17 Dec, 2025 | Andrew R Robbins | Stock Option (Right to Buy) | A | 245,000 | $0.00 | 245,000 | D | A |